[go: up one dir, main page]

HRP20161237T1 - Antimalarijski agensi - Google Patents

Antimalarijski agensi Download PDF

Info

Publication number
HRP20161237T1
HRP20161237T1 HRP20161237TT HRP20161237T HRP20161237T1 HR P20161237 T1 HRP20161237 T1 HR P20161237T1 HR P20161237T T HRP20161237T T HR P20161237TT HR P20161237 T HRP20161237 T HR P20161237T HR P20161237 T1 HRP20161237 T1 HR P20161237T1
Authority
HR
Croatia
Prior art keywords
phenyl
pyrazin
trifluoromethyl
amino
methanone
Prior art date
Application number
HRP20161237TT
Other languages
English (en)
Inventor
Yassir YOUNIS
Kelly Chibale
Michael John Witty
David Waterson
Original Assignee
University Of Cape Town
Mmv Medicines For Malaria Venture
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Cape Town, Mmv Medicines For Malaria Venture filed Critical University Of Cape Town
Publication of HRP20161237T1 publication Critical patent/HRP20161237T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Claims (21)

1. Aminopirazin prema Formuli (I), [image] naznačen time što je X CR1 ili N; Y je izabran iz skupine koju čine CF3, -C(O)NR3R4, O-R6 i SO2-R6; R1 je izabran između H i radikala halogenog elementa; R2 je izabran između SO2-R5 i -C(O)-R10; R3 i R4 su nezavisno izabrani između H i opcionalno supstituirane C1-C6 alkilne skupine; R5 je izabran između -NR7R8 i R9; R6 označava opcionalno supstituiranu C1-C6 alkilnu skupinu; R7 i R8 su nezavisno izabrani između H i opcionalno supstituirane C1-C6 alkilne skupine; R9 označava opcionalno supstituiranu C1-C6 alkilnu ili opcionalno supstituiranu C3-C8 cikloalkilnu skupinu; R10 označava NR11R12; a R11 i R12 su nezavisno izabrani između H i opcionalno supstituirane C1-C6 alkilne skupine ili NR11R12 zajedno čine opcionalno supstituiranu heterocikloalkilnu skupinu; kao i farmaceutski prihvatljive soli, komplekse, hidrate, solvate ili polimorfe, tautomere, geometrijske izomere, optički aktivne oblike, naznačeni time što se izraz „opcionalno supstituiran“ odnosi na grupe supstituirane s od 1 do 5 supstituenata izabranih iz skupine koju čine „C1-C6 alkil“, „C3-C8-cikloalkil“, „amino“, „hidroksi“, „nitro“ skupina i radikali halogenih elemenata.
2. Aminopirazin prema patentnom zahtjevu 1, naznačen time što X označava N.
3. Aminopirazin prema patentnom zahtjevu 1, naznačen time što X označava CR1 skupinu.
4. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time što Y označava CF3 skupinu.
5. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 3, naznačen time što Y označava -C(O)-NHR3 skupinu.
6. Aminopirazin prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time što Y označava SO2-R6 skupinu.
7. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time što R2 označava SO2-R5 skupinu.
8. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time što R2 označava SO2-R9 skupinu.
9. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time što R2 označava SO2-R9 skupinu i R9 označava opcionalno supstituiranu C1-C6 alkilnu skupinu.
10. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 6, naznačen time što R2 označava -C(O)-R10 skupinu.
11. Aminopirazin prema patentnom zahtjevu 10, naznačen time što NR11R12 čini opcionalno supstituiranu heterocikloalkilnu skupinu.
12. Aminopirazin prema patentnom zahtjevu 10, naznačen time što su R11 i R12 nezavisno izabrani između H i opcionalno supstituirane C1-C6 alkilne skupine.
13. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 12, naznačen time što je aminopirazin izabran iz skupine koju čine: 3-(6-metoksipiridin-3-il)-5-(4-(metilsulfonil)fenil)pirazin-2-amin; 5-(4-(metilsulfonil)fenil)-3-(4-(trifluorometil)fenil)pirazin-2-amin 5-(4-(metilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; 4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)benzamid; 4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)benzamid; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(4-metilpiperazin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(4-metil piperazin-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(piperazin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(piperazin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(morfolino)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(morfolino)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(4-metil-1,4-diazepan-1-il)metanon; 4-(5-amino-6-(3-fluoro-4-(trifluorometil)fenil)pirazin-2-il)benzamid; 4-(5-amino-6-(4-(metilsulfonil)fenil)pirazin-2-il)benzamid; 4,4'-(3-aminopirazin-2,6-diil)dibenzamid; 4-(3-amino-6-(4-karbamoilfenil)pirazin-2-il)-N-metilbenzamid; 4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)-N-metilbenzen sulfonamid; 5-(4-(etilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; 5-(4-(izopropilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(4-(terc-butil)piperazin-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(3-hidroksi-pirolidin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(4-hidroksi-piperidin-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(4-hidroksi-piperidin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(4-(tert-butil)piperazin-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(4-metil-1,4-diazepan-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(1,4-diazepan-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(1,4-diazepan-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(3-amino-pirolidin-1-il)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil) (3-amino-pirolidin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(3-hidroksi-pirolidin-1-il)metanon; (4-(5-amino-6-(6-(trifluorometil)piridin-3-il)pirazin-2-il)fenil)(4-aminocikloheksil)metanon; (4-(5-amino-6-(4-(trifluorometil)fenil)pirazin-2-il)fenil)(4-aminocikloheksil)metanon: 5-(4-(ciklopropilmetilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; i 5-(4-(ciklopropilsulfonil)fenil)-3-(6-(trifluorometil)piridin-3-il)pirazin-2-amin; kao i njihove farmaceutski prihvatljive soli, kompleksi, hidrati, solvati ili polimorfi, tautomeri, geometrijski izomeri, optički aktivni oblici i farmaceutski aktivni derivati.
14. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 13 za upotrebu kao lijek.
15. Farmaceutska formulacija koja sadrži najmanje jedan aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 13 i njezin farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
16. Farmaceutska formulacija prema patentnom zahtjevu 15 koja dalje sadrži antimalarijski agens.
17. Aminopirazin prema bilo kojem od patentnih zahtjeva od 1 do 13 za upotrebu u prevenciji i/ili liječenju malarije.
18. Postupak pripreme derivata aminopirazina prema Formuli (I) koji obuhvaća korak u kojem intermedijer Formule (v) reagira s boratnom kiselinom Formule (vi) u uvjetima Suzuki reakcije, čime nastaje spoj Formule (I): [image] , naznačen time što su X, Y, R1 i R2 kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva, a A označava [image] dok D označava: [image]
19. Postupak pripreme derivata aminopirazina prikazanog Formulom (I) koji obuhvaća korak u kojem derivat Formule (viii) reagira s boratnom kiselinom Formule (iv) u uvjetima Suzuki reakcije, čime nastaje spoj Formule (I): [image] , naznačen time što su A, D, X, Y, R1 i R2 kao što je to definirano u bilo kojem od prethodnih patentnih zahtjeva.
20. Intermedijer formule (viii) [image] , naznačen time što D označava [image] a R2 označava grupu definiranu u bilo kojem od prethodnih patentnih zahtjeva.
21. Intermedijer prema patentnom zahtjevu 20, naznačen time što intermedijer predstavlja 3-bromo-5-(4-(metilsulfonil)fenil)pirazin-2-amin ili (4-(5-amino-6-bromopirazin-2-il)fenil)(3-hidroksipirolidin-1-il)metanon.
HRP20161237TT 2012-02-17 2013-02-15 Antimalarijski agensi HRP20161237T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600324P 2012-02-17 2012-02-17
EP13712926.8A EP2814820B1 (en) 2012-02-17 2013-02-15 Anti-malarial agents
PCT/IB2013/051235 WO2013121387A1 (en) 2012-02-17 2013-02-15 Anti -malarial agents

Publications (1)

Publication Number Publication Date
HRP20161237T1 true HRP20161237T1 (hr) 2016-11-04

Family

ID=48014134

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161237TT HRP20161237T1 (hr) 2012-02-17 2013-02-15 Antimalarijski agensi

Country Status (20)

Country Link
US (1) US9266842B2 (hr)
EP (1) EP2814820B1 (hr)
JP (1) JP6226889B2 (hr)
CN (1) CN104136426B (hr)
BR (1) BR112014020212B1 (hr)
CA (1) CA2864483A1 (hr)
CY (1) CY1118074T1 (hr)
DK (1) DK2814820T3 (hr)
ES (1) ES2589283T3 (hr)
HR (1) HRP20161237T1 (hr)
HU (1) HUE029876T2 (hr)
IN (1) IN2014MN01622A (hr)
LT (1) LT2814820T (hr)
ME (1) ME02535B (hr)
PL (1) PL2814820T3 (hr)
PT (1) PT2814820T (hr)
SI (1) SI2814820T1 (hr)
SM (1) SMT201600441B (hr)
WO (1) WO2013121387A1 (hr)
ZA (1) ZA201406786B (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2814820T (lt) * 2012-02-17 2016-10-25 University Of Cape Town Antimaliariniai agentai
EP3118198A1 (en) 2015-07-13 2017-01-18 MMV Medicines for Malaria Venture Anti-malarial agents
WO2017067881A1 (en) 2015-10-19 2017-04-27 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds for use in the treatment of parasitic protozoal infections
WO2019145360A1 (en) * 2018-01-24 2019-08-01 Glaxosmithkline Intellectual Property Development Limited Novel compounds for the treatment of parasitic infections
CN112142715A (zh) * 2020-10-10 2020-12-29 鲁南制药集团股份有限公司 一种2-氨基-5-杂环基取代的吡嗪衍生物及其用途
AU2022395361A1 (en) * 2021-11-23 2024-05-30 Glaxosmithkline Intellectual Property Development Limited Pyrazine compounds useful in the treatment of parasitic protozoal infection
WO2024033281A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furo pyrimidine derivates
WO2024033280A1 (en) 2022-08-09 2024-02-15 Merck Patent Gmbh Furopyridin and furopyrimidin, inhibitors of pi4k, for use in the treatment of parasite infection and malaria

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1689715T3 (da) * 2003-12-03 2011-05-23 Ym Biosciences Australia Pty Tubulininhibitorer
DE602007004618D1 (de) 2006-06-22 2010-03-18 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk-kinaseinhibitoren
EP1900727A1 (en) * 2006-08-30 2008-03-19 Cellzome Ag Aminopyridine derivatives as kinase inhibitors
GB0625659D0 (en) * 2006-12-21 2007-01-31 Cancer Rec Tech Ltd Therapeutic compounds and their use
WO2011086531A2 (en) 2010-01-18 2011-07-21 Mmv Medicines For Malaria Venture New anti-malarial agents
JP2013529200A (ja) * 2010-05-12 2013-07-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
KR20140014205A (ko) * 2011-03-04 2014-02-05 렉시컨 파마슈티컬스 인코퍼레이티드 Mst1 키나제 억제제 및 그의 사용 방법
LT2814820T (lt) * 2012-02-17 2016-10-25 University Of Cape Town Antimaliariniai agentai

Also Published As

Publication number Publication date
ZA201406786B (en) 2015-06-24
HUE029876T2 (en) 2017-04-28
CN104136426A (zh) 2014-11-05
BR112014020212B1 (pt) 2021-11-23
BR112014020212A8 (pt) 2018-01-23
US20150031682A1 (en) 2015-01-29
PT2814820T (pt) 2016-10-25
JP6226889B2 (ja) 2017-11-08
ME02535B (me) 2017-02-20
US9266842B2 (en) 2016-02-23
EP2814820B1 (en) 2016-07-20
HK1202859A1 (en) 2015-10-09
CA2864483A1 (en) 2013-08-22
IN2014MN01622A (hr) 2015-05-15
CY1118074T1 (el) 2017-06-28
SI2814820T1 (sl) 2016-10-28
PL2814820T3 (pl) 2017-01-31
DK2814820T3 (en) 2016-10-03
SMT201600441B (it) 2017-01-10
ES2589283T3 (es) 2016-11-11
JP2015507004A (ja) 2015-03-05
WO2013121387A1 (en) 2013-08-22
EP2814820A1 (en) 2014-12-24
LT2814820T (lt) 2016-10-25
CN104136426B (zh) 2017-10-03

Similar Documents

Publication Publication Date Title
HRP20161237T1 (hr) Antimalarijski agensi
AU2014233414B2 (en) N-acyl-N'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
HRP20171453T1 (hr) Derivati imidazotiadiazola i imidazopirazina kao inhibitori proteazom aktiviranog receptora 4 (par4) za liječenje agregacije trombocita
PE20110835A1 (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
HRP20210459T1 (hr) Supstituirani derivati oksopiridina
RU2017122364A (ru) N-((гет)арилметил)-гетероарил-карбоксамидные соединения в качестве ингибиторов плазменного калликреина
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
HRP20241768T1 (hr) Heterociklički spoj
ME02409B (me) Novi heterociklični derivati i njihova upotreba u tretmanu neuroloških poremećaja
AU2018233402A1 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
JP2016506369A5 (hr)
AR053195A1 (es) Compuestos inhibidores de dipeptidil peptidasa-iv metodos para preparar los mismos y composiciones farmaceuticas que los contienen como un agente activo
BR112014019478A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, uso de um composto ou de um sal farmacologicamente aceitável do mesmo, formulação inibidor do canal de sódio, métodos para tratamento e/ou prevenção de dor e de uma doença.
SI2953948T1 (en) FLUORINATED INTEGRIN ANTAGONISTS
ME02664B (me) Derivati premeštanja piridina u toku transfekcije inhibitora (ret) kinaze
JP2016517417A5 (hr)
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
NZ627750A (en) Carbamate compounds and of making and using same
NZ731337A (en) Compounds useful as inhibitors of atr kinase
NZ629282A (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
RU2019114600A (ru) Соединение аминопиразолопиримидина, используемое в качестве ингибитора тирозинкиназного рецептора нейротрофического фактора
UY33606A (es) DERIVADOS DE PIRAZINA COMO BLOQUEADORES DE ENaC
AR079199A1 (es) Composiciones farmaceuticas que comprenden ligandos de receptores sigma
CY1124245T1 (el) Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka